About Lygos
Lygos is a company based in Emeryville (United States) founded in 2010 by Eric Steen. It operates as a B2B2C. Lygos has raised $51.77 million across 24 funding rounds from investors including United States Department of Agriculture, Flexible Solutions and DOE. Lygos has completed 1 acquisition, including Librede. Lygos offers products and services including Soltellus TM, Agronomy Solutions, Home Care Solutions, Hygiene Solutions, and Personal Care Solutions. Lygos operates in a competitive market with competitors including Avidity Biosciences, Univercells, Sutro Biopharma, Evonik and Vividion Therapeutics, among others.
- Headquarter Emeryville, United States
- Founders Eric Steen
-
Sectors
Chemicals & MaterialsHealthcare
-
Phone
Locked
-
Website
Locked
-
Social
Locked
- Legal Name Lygos, Inc.
-
Annual Revenue
Not available
-
Net Profit
Not available
-
EBITDA
Not available
-
Total Equity Funding
$51.77 M (USD)
in 24 rounds
-
Latest Funding Round
Not available
-
Investors
United States Department of Agriculture
& 16 more
-
Employee Count
Not available
- Investments & Acquisitions
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Products & Services of Lygos
Lygos offers a comprehensive portfolio of products and services, including Soltellus TM, Agronomy Solutions, Home Care Solutions, Hygiene Solutions, and Personal Care Solutions.
Specialty chemicals are developed for various industrial applications.
Solutions are provided to increase crop yields effectively.
Products are designed to remove soil and stains.
Polymers are created for high performance and sustainability.
Formulations are improved for haircare and skincare products.
Chemicals are used to prevent scale and corrosion.
People of Lygos
Unlock access to complete
Unlock access to complete
Funding Insights of Lygos
Lygos has successfully raised a total of $51.77M across 24 strategic funding rounds. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
Investors in Lygos
Lygos has secured backing from 17 investors, including institutional and venture fund investors. Prominent investors backing the company include United States Department of Agriculture, Flexible Solutions and DOE.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Investment in early-stage companies across AI, biotech, and cleantech sectors with access to global resources.
|
Locked | Locked | Locked | |
|
Seed and early-stage venture capital firm focusing on investments in technology and fintech companies
|
Locked | Locked | Locked | |
|
US focused seed and early-stage VC firm
|
Locked | Locked | Locked |
Investor details for Lygos
Investor domains, locations, round participation, and complete history require an active premium plan.
- Investor domains
- Investor locations
- Funding rounds
- Participation history
Verified entity values are shown only after access is granted.
Investments & Acquisitions by Lygos
Lygos has strategically engaged in corporate development activities, having acquired 1 company. Notable acquisitions include Librede.
Investment portfolio details for Lygos
Portfolio company identities, transaction dates, round details, and investment values require an active premium plan.
- Portfolio identities
- Transaction dates
- Round details
- Investment values
Verified entity values are shown only after access is granted.
| Company Name | Description | Domain | Location | Founded Year | Amount |
|---|---|---|---|---|---|
|
Yeast is engineered via synthetic biology for cannabinoid compound production.
|
Locked | Locked | 2009 | Locked |
Complete acquisition details for Lygos
Transaction dates, acquired stakes, disclosed values, domains, and locations require an active premium plan.
- Transaction dates
- Acquired stakes
- Disclosed values
- Domains and locations
Verified entity values are shown only after access is granted.
Financial Statements - Lygos
Detailed financials for Lygos
Historical revenue, profit, statement rows, ratios, and trend charts require an active premium plan.
- Historical revenue
- Profit trends
- Statement rows
- Financial ratios
Verified entity values are shown only after access is granted.
Lygos Comparisons
Peer comparison for Lygos
Named peer metrics, headcount, funding, location, and side-by-side benchmarks require an active premium plan.
- Named peers
- Headcount comparison
- Funding comparison
- Operating benchmarks
Verified entity values are shown only after access is granted.
Competitors of Lygos
Lygos operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Avidity Biosciences, Univercells, Sutro Biopharma, Evonik and Vividion Therapeutics, among others.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| Locked | Locked | Locked |
Antibody-siRNA complexes are developed for cancer treatment.
|
|
| Locked | Locked | Locked |
Biomanufacturing technologies are supplied for biopharma antibody and vaccine production.
|
|
| Locked | Locked | Locked |
Antibody-based therapeutics for cancer therapy are developed via cell-free synthesis.
|
|
| Locked | Locked | Locked |
Green specialty chemicals are developed and supplied for multiple industries.
|
|
| Locked | Locked | Locked |
Developing novel drugs based on a proteome-wide ligand and target discovery platform
|
|
| Locked | Locked | Locked |
RNA-editing technologies are provided for precision medicine applications.
|
Detailed competitors of Lygos
Competitor domains, locations, full profiles, and operating metrics require an active premium plan.
- Domains and locations
- Full company profiles
- Operating metrics
- Competitive positioning
Verified entity values are shown only after access is granted.
Latest news on Lygos
Complete news archive for Lygos
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Lygos
Lygos was founded in 2010 and raised its 1st funding round 1 year after it was founded.
Lygos is headquartered in Emeryville, United States. It is registered at Emeryville, California, United States.
Eric Steen is the current CEO of Lygos. They have also founded this company.
Lygos is a funded company, having raised a total of $51.77M across 24 funding rounds to date.
Specialty chemicals are produced by Lygos to enhance performance across multiple sectors including agronomy, home care, hygiene, personal care, and water treatment. Solutions are designed to improve crop yields, fight stains, balance sustainability with performance, enhance personal care formulations, and prevent corrosion in water systems. Practical innovations are delivered through material science and chemistry expertise, ensuring sustainable value at scale for customers without compromising on quality.
Lygos's top competitors include Sutro Biopharma, Avidity Biosciences and Antheia.
Lygos offers Soltellus TM, Agronomy Solutions, Home Care Solutions, Hygiene Solutions, and 2 more products and services.
Lygos has made 1 acquisition, including Librede.
Lygos has 17 investors. Key investors include United States Department of Agriculture, Flexible Solutions, DOE, NanoChem Solutions, and LG Technology Ventures.